CD81 and acute myeloid leukemia: To validate Egln3 as a downstream effector of MIF, we overexpressed Egln3 (Egln3_OE) in AML cells and cocultured them with Δ/Δ CD81+ Erys for 9 days (Figure 7D and Supplemental Figure 8G).